Tuberculosis preventive treatment uptake among adults living with human immunodeficiency virus: Analysis of Zimbabwe population-based human immunodeficiency virus impact assessment 2020

Tuberculosis remains the leading cause of death by an infectious disease among people living with HIV (PLHIV). TB Preventive Treatment (TPT) is a cost-effective intervention known to reduce morbidity and mortality. We used data from ZIMPHIA 2020 to assess TPT uptake and factors associated with its u...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of STD & AIDS Vol. 35; no. 8; p. 593
Main Authors:	Maphosa, Talent, Mirkovic, Kelsey, Weber, Rachel A, Musuka, Godfrey, Mapingure, Munyaradzi P, Ershova, Julia, Laws, Rebecca, Dobbs, Trudy, Coggin, William, Sandy, Charles, Apollo, Tsitsi, Mugurungi, Owen, Melchior, Michael, Farahani, Mansoor S
Format:	Journal Article
Language:	English
Published:	England 01-07-2024
Subjects:	Adolescent Adult Antitubercular Agents - therapeutic use Cross-Sectional Studies Female HIV Infections - epidemiology HIV Infections - prevention & control Humans Male Middle Aged Patient Acceptance of Health Care - statistics & numerical data Tuberculosis - epidemiology Tuberculosis - prevention & control Young Adult Zimbabwe - epidemiology Zimbabwe TB screening Leave out Zimbabwe population-based HIV impact assessment people living with human immunodeficiency virus Zimbabwe isoniazid preventive therapy Tuberculosis preventive treatment tuberculosis screening, tuberculosis, human immunodeficiency virus
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	Tuberculosis remains the leading cause of death by an infectious disease among people living with HIV (PLHIV). TB Preventive Treatment (TPT) is a cost-effective intervention known to reduce morbidity and mortality. We used data from ZIMPHIA 2020 to assess TPT uptake and factors associated with its use. ZIMPHIA a cross-sectional household survey, estimated HIV treatment outcomes among PLHIV aged ≥15 years. Randomly selected participants provided demographic and clinical information. We applied multivariable logistic regression models using survey weights. Variances were estimated via the Jackknife series to determine factors associated with TPT uptake. The sample of 2419 PLHIV ≥15 years had 65% females, 44% had no primary education, and 29% lived in urban centers. Overall, 38% had ever taken TPT, including 15% currently taking TPT. Controlling for other variables, those screened for TB at last HIV-related visit, those who visited a TB clinic in the previous 12 months, and those who had HIV viral load suppression were more likely to take TPT. The findings show suboptimal TPT coverage among PLHIV. There is a need for targeted interventions and policies to address the barriers to TPT uptake, to reduce TB morbidity and mortality among PLHIV.
ISSN:	1758-1052
DOI:	10.1177/09564624241239186